ZA913865B - Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases - Google Patents

Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases

Info

Publication number
ZA913865B
ZA913865B ZA913865A ZA913865A ZA913865B ZA 913865 B ZA913865 B ZA 913865B ZA 913865 A ZA913865 A ZA 913865A ZA 913865 A ZA913865 A ZA 913865A ZA 913865 B ZA913865 B ZA 913865B
Authority
ZA
South Africa
Prior art keywords
naphthylethyl
tetrahydropyridine
trifluoromethylphenyl
cerebral
medicament
Prior art date
Application number
ZA913865A
Other languages
English (en)
Inventor
Francois Xavier Goude
Xavier Goude Francois
Jacqueline Fournier
Fournier Jacqueline
Umberto Guzzi
Guzzi Umberto
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA913865B publication Critical patent/ZA913865B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA913865A 1990-05-22 1991-05-22 Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases ZA913865B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
ZA913865B true ZA913865B (en) 1992-02-26

Family

ID=9396855

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913865A ZA913865B (en) 1990-05-22 1991-05-22 Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases

Country Status (17)

Country Link
US (3) US5229389A (xx)
EP (2) EP0655247B1 (xx)
JP (2) JP2618115B2 (xx)
KR (1) KR0181330B1 (xx)
AT (2) ATE207747T1 (xx)
BR (1) BR9105015A (xx)
CA (2) CA2042974C (xx)
CY (1) CY2283B1 (xx)
DE (2) DE69115989T2 (xx)
DK (2) DK0458696T3 (xx)
FR (1) FR2662355B1 (xx)
HK (1) HK1001471A1 (xx)
HU (1) HU208922B (xx)
IE (1) IE911707A1 (xx)
IL (3) IL112167A (xx)
TW (1) TW216771B (xx)
ZA (1) ZA913865B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
NZ320355A (en) * 1995-10-26 2000-03-27 Sanofi Sa Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
AU719038B2 (en) * 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
WO1998033502A1 (fr) * 1997-02-03 1998-08-06 Sanofi-Synthelabo Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
CA2042974C (en) 2002-09-17
US5229389A (en) 1993-07-20
FR2662355B1 (fr) 1994-11-10
IL98175A0 (en) 1992-06-21
EP0655247A1 (fr) 1995-05-31
DK0458696T3 (da) 1996-05-20
DE69132797T2 (de) 2002-05-29
CA2365832C (en) 2007-08-07
KR0181330B1 (ko) 1999-03-20
DK0655247T3 (da) 2002-02-18
HU911729D0 (en) 1991-12-30
CA2042974A1 (en) 1991-11-22
IL112167A (en) 1996-01-31
BR9105015A (pt) 1993-05-25
IE20011078A1 (en) 2002-03-20
ATE207747T1 (de) 2001-11-15
EP0458696A2 (fr) 1991-11-27
IE911707A1 (en) 1991-12-04
HK1001471A1 (en) 1998-06-19
AU7713391A (en) 1991-11-28
CA2365832A1 (en) 1991-11-23
EP0458696A3 (en) 1992-03-18
JP2954029B2 (ja) 1999-09-27
DE69132797D1 (de) 2001-12-06
EP0458696B1 (fr) 1996-01-03
CY2283B1 (en) 2003-07-04
EP0655247B1 (fr) 2001-10-31
IL98175A (en) 1996-01-19
TW216771B (xx) 1993-12-01
JP2618115B2 (ja) 1997-06-11
DE69115989D1 (de) 1996-02-15
JPH04226917A (ja) 1992-08-17
DE69115989T2 (de) 1996-08-22
US5468753A (en) 1995-11-21
AU636488B2 (en) 1993-04-29
ATE132369T1 (de) 1996-01-15
IL112167A0 (en) 1995-03-15
HUT59824A (en) 1992-07-28
JPH09132535A (ja) 1997-05-20
US5270320A (en) 1993-12-14
KR910019617A (ko) 1991-12-19
FR2662355A1 (fr) 1991-11-29
HU208922B (en) 1994-02-28

Similar Documents

Publication Publication Date Title
ZA913865B (en) Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases
McNaughton et al. Reticular stimulation and hippocampal theta rhythm in rats: effects of drugs
DE3886768D1 (de) Vorrichtung zum herstellen von kunststoff-formteilen und verwendung der vorrichtung.
DE69435246D1 (de) Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung der senilen Demenz und Alzheimer-Erkrankung
DE3889087D1 (de) Integrierter Tintenspritzdruckkopf und Verfahren zu dessen Herstellung.
DE69534002D1 (de) Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserung der Gehirntätigkeit
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
ATE100322T1 (de) Verwendung von uridin zur behandlung nervoeser stoerungen.
ATE254172T1 (de) Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase
McGinty et al. Neuronal unit activity patterns in behaving animals: brainstem and limbic system.
ATE131056T1 (de) Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen.
DE60026501D1 (en) Humane hirn-spezifische carboxypeptidase b
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
DK0389425T3 (da) Benzothiopyranylaminer
PT79928B (de) Verfahren zur herstellung von 1,3,2-dioxaborinan und von bioziden verbindungen die sie enthalten
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
DE3870912D1 (de) 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon.
PT76582A (de) 1,2,4-triazol-1-yl-propionitrile verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel
Gilden Dual action effects of morphine on the electrical activity of the dorsal tegmentum
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
ATE104283T1 (de) N-(substituiertes alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.
IT8718301A0 (it) Scatola di sicurezza per aghi usati nelle iniezioni e nei prelievi di sangue.